Coronary Artery Disease Prevalent Among Hodgkin Lymphoma Survivors

Share this content:

the Cancer Therapy Advisor take:

Cardiovascular diseases are a common cause of death among survivors of Hodgkin lymphoma. To evaluate the prevalence of coronary artery disease (CAD) in this patient population, researchers evaluated 48 survivors of Hodgkin lymphoma who were treated with mediastinal irradiation and had been disease-free for 10 years using electrocardiogram, exercise testing, and computed tomographic coronary angiography (CTA). Results indicated that 20% of patients had significant CAD on CTA, which was considerably higher than the 7% expected abnormalities. Significant stenosis was found and subsequent revascularization was performed in 11%. The researchers concluded that this study suggests CTA screening may be beneficial for survivors of Hodgkin lymphoma, but requires examination in a larger cohort. 

Coronary Artery Disease Prevalent Among Hodgkin Lymphoma Survivors
Coronary Artery Disease Prevalent Among Hodgkin Lymphoma Survivors

We investigated the role of computed tomographic coronary angiography (CTA) as a screening tool for coronary artery disease (CAD) in asymptomatic Hodgkin lymphoma survivors, and related CTA findings to exercise testing and subsequent interventions. Patients and methods Patients were eligible for this phase II study if at least 10 years disease-free and treated with mediastinal radiotherapy.

READ FULL ARTICLE From Annals of Oncology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs